Medincell
French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. Its thesis rests on a royalty model from partnerships with major pharma companies.
Investment thesis
- 01
Patented BEPO® platform, already validated through regulatory approvals — a durable and repeatable competitive moat.
- 02
Asset-light model: commercialisation outsourced to industrial partners (Teva, AbbVie); Medincell captures the upside through royalties and milestone payments.
- 03
First marketed product (UZEDY®, schizophrenia, Teva partnership) already generating royalty inflows, securing the funding runway.
- 04
Diversified pipeline beyond psychiatry: ophthalmology, pain, antiparasitics.
- 05
Reformulation potential for existing molecules: lower scientific risk than greenfield development, shorter time-to-market.
Catalysts
Olanzapine LAI (TEV-‘749) — US regulatory milestones
Continued FDA regulatory progression of the long-acting olanzapine developed with Teva, a defining candidate for the psychiatry pipeline.
UZEDY® royalty trajectory
Quarterly read of prescription ramp-up and associated royalty flow: a direct gauge of Teva's execution quality and of market uptake.
New partnerships / platform extensions
Medincell's ability to sign new deals (reformulations of existing molecules): a key signal of the platform's perceived value across the industry.
Ophthalmology progress (AbbVie partnership)
Clinical milestones on ophthalmic programmes co-developed with AbbVie, diversifying the thesis beyond central nervous system applications.
Annual general meeting
A moment of dialogue with management on partnership strategy, capital allocation and the financial trajectory.
Risks
Short-term revenue concentration
At this stage, recurring revenue rests largely on UZEDY® through Teva: diversification is being built but is not yet effective.
Dependence on partner commercial choices
Medincell does not directly control pricing, reimbursement or sales force decisions: the P&L depends on partners.
Regulatory and clinical timelines
Pipeline programmes remain subject to the usual hazards of clinical development and FDA / EMA decisions.
Valuation multiple volatility
The market oscillates between a pharma-services reading (royalties) and a biotech reading (pipeline), with significant multiple gaps.
Calendar
- 2026Half-year resultsEarnings
- 2026Annual general meetingAGM
- 2026Partner pipeline milestonesClinical
Governance
Stable historical leadership around the co-founders. Capital open to an international institutional shareholder base and a solid retail shareholder community, especially active at AGMs. Capcordia documents resolutions, votes and management communications.
This file is editorial and does not constitute investment advice. Individual shareholders are responsible for their own decisions.